Loading...
MCRB logo

Seres Therapeutics, Inc.NasdaqGS:MCRB Stock Report

Market Cap US$68.6m
Share Price
n/a
1Y-22.2%
7D7.1%
1D3.4%
Portfolio Value
​
View

Seres Therapeutics, Inc.

NasdaqGS:MCRB Stock Report

Market Cap: US$68.6m

Seres Therapeutics (MCRB) Stock Overview

A clinical-stage company, focuses on developing biotherapeutics for serious diseases. More details

MCRB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Earnings have grown 11.3% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 28.7% per year for the next 3 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue ($1M)

+ 1 more risk

MCRB Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Seres Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Seres Therapeutics
Historical stock prices
Current Share PriceUS$7.08
52 Week HighUS$29.98
52 Week LowUS$5.31
Beta0.11
1 Month Change-3.28%
3 Month Change-19.55%
1 Year Change-22.20%
3 Year Change-92.61%
5 Year Change-98.33%
Change since IPO-99.31%

Recent News & Updates

Analysis Article • Jun 13

Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

Analysis Article • Jun 13

Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Feb 06

Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'

Summary Seres Therapeutics sold VOWST to Nestlé in 2024. This helped validate their microbiome therapeutics. This sale also helped them extend their runway into Q2 2026 after a 25% workforce reduction. Their next value driver will come with SER-155’s Phase 2 for gut-driven bloodstream infections in allo-HSCT patients. The initial Phase 1b showed 77% relative BSI risk reduction with favorable safety, and the FDA gave it a Breakthrough designation. MCRB’s valuation still looks relatively reasonable. But, as a thinly traded microcap, any dilution concerns are heightened. Thus, I think it’s better to rate it a “Hold” today. Read the full article on Seeking Alpha
Analysis Article • Nov 15

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

The Seres Therapeutics, Inc. ( NASDAQ:MCRB ) share price has fared very poorly over the last month, falling by a...
Seeking Alpha • Sep 23

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Summary Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also gets potential future milestone payments of up to $275 million. Promising Phase 1b data for SER-155 shows potential in preventing bacterial infections in immunocompromised patients, positioning it as a new value driver. Favorable SER-155 results and potential FDA Breakthrough Therapy Designation could expedite regulatory approval, enhancing MCRB's investment appeal. Despite selling its most valuable IP, MCRB's valuation now looks compelling, making it a speculative "buy" for investors aware of its inherent biotech and cash runway risks. Read the full article on Seeking Alpha
Analysis Article • Jul 13

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shares have continued their recent momentum with a 44% gain in the last month...
Analysis Article • May 08

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shares have had a really impressive month, gaining 46% after a shaky period...
Analysis Article • Mar 23

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Unfortunately for some shareholders, the Seres Therapeutics, Inc. ( NASDAQ:MCRB ) share price has dived 30% in the last...
Seeking Alpha • Jan 30

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Summary Seres Therapeutics focuses on microbiome therapies, with its leading product VOWST preventing recurrent Clostridioides difficile infection. The company is developing SER-155, which has FDA Fast Track Designation, and has other products in its pipeline for ulcerative colitis and oncology applications. Despite promising research, due to the company's financing concerns and heavy short interest, I rate it a "sell" for now. Still, I discourage shorting the shares as many potential unforeseen catalysts could squeeze the shares higher. I think shorting at this point is too risky. Read the full article on Seeking Alpha
Analysis Article • Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

To the annoyance of some shareholders, Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shares are down a considerable 30% in...
Analysis Article • Aug 31

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

The Seres Therapeutics, Inc. ( NASDAQ:MCRB ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Aug 09

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

MCRBUS BiotechsUS Market
7D7.1%7.5%-2.5%
1Y-22.2%40.9%19.0%

Return vs Industry: MCRB underperformed the US Biotechs industry which returned 40.6% over the past year.

Return vs Market: MCRB underperformed the US Market which returned 20% over the past year.

Price Volatility

Is MCRB's price volatile compared to industry and market?
MCRB volatility
MCRB Average Weekly Movement8.3%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: MCRB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MCRB's weekly volatility has decreased from 14% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201066Rich Kenderwww.serestherapeutics.com

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease.

Seres Therapeutics, Inc. Fundamentals Summary

How do Seres Therapeutics's earnings and revenue compare to its market cap?
MCRB fundamental statistics
Market capUS$68.56m
Earnings (TTM)-US$46.90m
Revenue (TTM)US$1.15m
59.8x
P/S Ratio
-1.5x
P/E Ratio

Is MCRB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCRB income statement (TTM)
RevenueUS$1.15m
Cost of RevenueUS$53.45m
Gross Profit-US$52.30m
Other Expenses-US$5.40m
Earnings-US$46.90m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-4.84
Gross Margin-4,560.07%
Net Profit Margin-4,088.84%
Debt/Equity Ratio0%

How did MCRB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 02:41
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seres Therapeutics, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
John NewmanCanaccord Genuity
John TannerCantor Fitzgerald & Co.